Drug reference

elotuzumab

humanized IgG1, anti-SLAMF7 (CD319) · anticancer

humanized IgG1, anti-SLAMF7 (CD319)anticancer

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter
CladribineSevereDatabaseDDInter

Mechanism

Elotuzumab is a humanized IgG1 that targets SLAMF7 (CD319), a cell surface glycoprotein expressed on MM and NK cells. Binding of elotuzumab to the antigen on myeloma cells induces ADCC-dependent tumor cell lysis, enhanced by stimulation of the SLAMF7 pathway in NK cells.

Indications

multiple myeloma (MM) who have received one to three prior therapies (used in combination with lenalidomide and dexamethasone)Relapsed multiple myeloma

Side effects

Common

infusion reaction

Drug interactions

Adalimumab

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Baricitinib

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Certolizumab

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Cladribine

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Etanercept

Severe

Database

Clinical effect not specified

Source: DDInter

Fingolimod

Severe

Database

Clinical effect not specified

Source: DDInter

Golimumab

Severe

Database

Clinical effect not specified

Source: DDInter

Infliximab

Severe

Database

Clinical effect not specified

Source: DDInter

Leflunomide

Severe

Database

Clinical effect not specified

Source: DDInter

Lomitapide

Severe

Database

Clinical effect not specified

Source: DDInter

Measles Virus Vaccine Live Attenuated

Severe

Database

Clinical effect not specified

Source: DDInter

Mipomersen

Severe

Database

Clinical effect not specified

Source: DDInter

Related guidelines

Multifetal pregnancy

FOGSI · Obstetrics & Gynaecology · 2024

Heart failure in diabetes

RSSDI · Cardiology · 2023

Pulmonary tuberculosis

RNTCP · Infectious Disease · 2023

Dyslipidaemia in diabetes

RSSDI · Endocrinology · 2022

Depression in adults

NICE · Psychiatry · 2022

Ask House about elotuzumab

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team